- ResApp Health (RAP) has partnered with HealthEngine to integrate its booking engine into ResApp’s mobile medical app, SleepCheck
- SleepCheck analyses users breathing and snoring sounds during sleep to monitor whether they’re at risk of obstructive sleep apnoea (OSA)
- HealthEngine has helped over seven million Australians make more than 30 million in-person and telehealth bookings through its online platform
- Under the deal, SleepCheck users will be directed to book consultations through the HealthEngine platform if they’re deemed at risk of OSA
- ResApp will retain all revenues from SleepCheck downloads and will also receive a royalty from HealthEngine for every new patient referred
- It’s unknown exactly how much the agreement will bring in, but ResApp is confident of significant consumer uptake
- ResApp Health is trading 10 per cent higher for 11 cents per share
ResApp Health (RAP) has partnered with HealthEngine to integrate its booking engine into ResApp’s mobile medical app, SleepCheck.
The deal
HealthEngine is a platform which helps patients find, book and connect with
healthcare service providers through its online booking network.
The platform boasts Australia’s largest online patient network, and has helped over seven million Australians make more than 30 million in-person and telehealth bookings online.
The agreement will see ResApp integrate HealthEngine’s booking network into its SleepCheck app, and HealthEngine will promote the use of SleepCheck.
SleepCheck analyses users breathing and snoring sounds during sleep to monitor whether they’re at risk of obstructive sleep apnoea (OSA).
If SleepCheck identifies that a user is at risk of OSA, it directs them to see a doctor.
Integrating HealthEngine’s booking engine directly into the app will allow users to book an appointment with their GP or another healthcare professional through a dedicated landing page managed by HealthEngine.
The initial agreement is for 12 months, which can be extended by agreement of both parties.
Booking fees
ResApp will retain all revenues from downloads of the SleepCheck app. The company will also receive a royalty from HealthEngine for every new patient referred through SleepCheck.
At this stage, ResApp can’t project the possible windfall from the agreement, but believes the effect will be material.
ResApp CEO and Managing Director Dr Tony Keating says the agreement is a win-win.
“This partnership is a tremendous achievement for ResApp and highlights SleepCheck’s potential in the Australian market,” Dr Keating said.
“The agreement with HealthEngine provides us with access to a trusted and reliable consumer healthcare network, which will further improve our offering by allowing users to immediately progress the treatment journey,” he continued.
“This agreement is further evidence of ResApp’s ability to attract large, industry-leading partners that it can leverage to drive growth well into the future.”
Dr Tony Keating, ResApp CEO and Managing Director
ResApp also has a number of other partnership agreements pending, which will provide further possibilities to enlarge the company’s market footprint.
ResApp Health is trading 10 per cent higher for 11 cents per share at 11:17 am AEDT.